Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia in adult patients by targeting the BCR‑ABL protein.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support, batch traceability, and on‑time delivery to meet clinical trial and treatment needs.

Nilotinib is a targeted therapy used in the treatment of Philadelphia chromosome‑positive chronic myeloid leukemia.

- Chronic myeloid leukemia (chronic phase): improves hematologic and cytogenetic response, delaying disease progression. - Chronic myeloid leukemia (accelerated phase): achieves disease control and reduces blast counts. - Chronic myeloid leukemia (blast phase): provides therapeutic benefit when combined with other agents.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash or skin irritation - Headache - Fatigue - Muscle aches

Serious or Rare Side Effects: - QT interval prolongation leading to arrhythmia - Pancreatitis - Elevated liver enzymes or hepatic failure - Severe neutropenia or thrombocytopenia - Cardiovascular events such as myocardial infarction - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis)

When prescribing Nilotinib, clinicians should observe several safety measures to minimize risk.

- ECG monitoring: perform baseline and periodic ECGs to detect QT prolongation. - Liver function tests: assess hepatic enzymes before and during therapy. - Blood glucose: monitor fasting glucose as hyperglycemia may occur. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors that can increase plasma levels. - Pregnancy and lactation: drug is contraindicated; assess risk‑benefit before use in women of child‑bearing potential. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Nilotinib interacts with several medicines through metabolic pathways and cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib concentrations and increase toxicity. - QT‑prolonging agents (e.g., amiodarone, sotalol): additive risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may require dose adjustment. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure. - Warfarin: monitor INR as Nilotinib can affect anticoagulation. - Digoxin: observe serum levels for potential increase.